The team of the Chinese Academy of Sciences has developed therapeutic antibodies for new coronary pneumonia into clinical trials

BEIJING, June 6 (Xinhua Sun Zifa) China's
Institute of Microbiology announced through the official network platform on the 6th, the new coronavirus all-human monoclonal antibody developed by the anti-epidemic science and technology team of the new application for clinical trials, 5 has been officially approved by the State Drug Administration, its Phase I clinical trials will be in healthy people for safety and dose testing.
This is the world's first non-human primate experiments, in a healthy population of new pneumonia therapeutic antibody clinical trials, marking China's independent intellectual property rights of the new coronavirus-specific antibody drugs, has successfully entered the human clinical evaluation stage.
From mid-January this year,
microorganisms quickly set up a number of anti-epidemic science and technology team, Yan Jinghua researchers team in antibody drugs day and night hard work, from the new corona pneumonia healed out of the hospital patients isolated identified dozens of all-human antibody genes, after trial and error comparison, in late February screened out 2 ideal special antibodies, with high efficiency and the activity of the new coronavirus.
team used the rhesus monkey new coronavirus infection model to evaluate the effectiveness of antibodies, the results show that: the antibody effectively blocked the infection of the new coronavirus, significantly reduced the load of the rhesus monkey respiratory tract of the new coronavirus, to protect the lung damage caused by the virus infection.
Neutral antibody is a class of specific immunity
that targets pathogens and blocks pathogen invading cells, and is an innovative special effects drug developed for the new coronavirus, and the clinical trial of antibody drugs has brought new hope to curb the spread of the new coronavirus. The team also cautions that there is still a long way to go, from entering the human clinical trial phase to the eventual use of antibody drugs.
Previously, the
Institute of Microbiology research team in the United Nations in late May in the international authoritative academic journal Nature published an important research paper on the new coronavirus online, the first reported in the non-human primate experimental model, can effectively treat and prevent new coronavirus infection specific, all-human monoclonal antibodies.